SCHEMBL19486455

SCHEMBL19486455

Cn1c2ncccc2n2c3ccccc3nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
ATM Q13315 1/20 0.41
KDM4E B2RXH2 3/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HSD17B10 Q99714 2/20 0.41
LMNA P02545 1/20 0.41
TP53 P04637 1/20 0.41
POLB P06746 1/20 0.41
BRD4 O60885 1/20 0.40
FGFR1 P11362 1/20 0.40
HTR3E A5X5Y0 2/20 0.39
HTR3B O95264 2/20 0.39
HTR3A P46098 2/20 0.39
HTR3D Q70Z44 2/20 0.39
HTR3C Q8WXA8 2/20 0.39
CYP19A1 P11511 1/20 0.39
HTR1A P08908 1/20 0.38
HTR2C P28335 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17849983 0.87 ATM (0.45) SMN1; SMN2ATMKDM4EMAPTMEN1
SCHEMBL18083287 0.82 SMN1; SMN2 (0.55) SMN1; SMN2ATMKDM4EMAPTMEN1
SCHEMBL21101316 0.81 KDM4E (0.37) SMN1; SMN2KDM4EMAPTMEN1KMT2A
SCHEMBL17570852 0.81 ATM (0.41) SMN1; SMN2ATMKDM4EMAPTMEN1
SCHEMBL12799837 0.79 ATM (0.53) SMN1; SMN2ATMKDM4EMAPTMEN1
SCHEMBL25708331 0.73 ATM (0.47) SMN1; SMN2ATMKDM4EMEN1KMT2A
SCHEMBL17570864 0.73 MEN1 (0.50) SMN1; SMN2ATMKDM4EMAPTMEN1
SCHEMBL17570839 0.73 MEN1 (0.50) SMN1; SMN2ATMKDM4EMAPTMEN1
SCHEMBL26168128 0.73 SMN1; SMN2 (0.48) SMN1; SMN2ATMKDM4EMAPTMEN1
SCHEMBL22380184 0.72 BRD4 (0.38) SMN1; SMN2ATMKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10968229-B2 Seven-membered ring compounds IDEMITSU KOSAN CO., LTD. (JP) 2021-04-06 US disclosed
US-20190245152-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2019-08-08 US disclosed
EP-2993215-B1 Azabenzimidazo[2,1-a]benzimidazoles for electronic applications IDEMITSU KOSAN CO (JP) 2019-06-19 EP disclosed
US-20190119291-A1 SEVEN-MEMBERED RING COMPOUNDS IDEMITSU KOSAN CO., LTD. (JP) 2019-04-25 US disclosed
WO-2017178864-A1 SEVEN-MEMBERED RING COMPOUNDS IDEMITSU KOSAN CO., LTD. (JP) 2017-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119291-A1 SEVEN-MEMBERED RING COMPOUNDS MCM7, XPO7, LUC7L2 SMN1; SMN2 3354/4885ATM 4103/4885KDM4E 2621/4885
US-10968229-B2 Seven-membered ring compounds MCM7, XPO7, LUC7L2 SMN1; SMN2 3354/4885ATM 4103/4885KDM4E 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.